The analysis also shows real-world evidence of the vaccine's effectiveness against a highly infectious variant of COVID-19 first discovered in Britain, known as B.1.1.7
Company was the first vaccine maker to apply for an emergency-use authorisation in India.
The European Union mentioned Tyrol in Austria, Nice and Moselle in France, Bolzano in Italy and some parts of Bavaria and Saxony in Germany where COVID-19 hospitalisations have been on the rise
A new study suggests that the Pfizer-BioNtech Covid-19 vaccine can protect people against the concerning coronavirus variant first identified in Brazil
Gopinath praised India for playing a very important role during the crisis by manufacturing and shipping the Covid vaccines to several nations
The vaccines appear significantly less effective against the Covid variant that first emerged in South Africa, the study finds
Experts say the new analysis adds to growing evidence that the vaccines are working
Japan has received its third batch of the Pfizer Covid-19 vaccine, with the shipment containing up to 526,500 doses developed by US pharmaceutical giant and its German partner BioNTech
The Food and Drug Administration said Thursday that it's allowing the additional option after reviewing new data from New York-based Pfizer and its German partner, BioNTech
The companies believe their current two-dose vaccine will work against the South African variant as well as one found in the United Kingdom and elsewhere
The vaccine was 92 percent effective at preventing severe disease after two shots and 62 percent after one
It is the first coronavirus shot to receive full approval in Brazil, regulator Anvisa said. Vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use
This provides the first indication that the immunisation will curb transmission
Pfizer CEO Albert Bourla said the company expects to double its rollout of coronavirus vaccines to 10 million a week over the next two weeks as Biden pledged enough supply of doses by July
Fresh Pfizer-BioNTech data shows coronavirus vaccine easier to use
Pfizer/BioNTech's vaccine, along with Moderna Inc's two-dose shot, won the US emergency use authorization (EUA) and is being widely distributed as part of the country's mass vaccination efforts
If approved, this new storage option would offer pharmacies and vaccination centers greater flexibility in how they manage their vaccine supply
Only about 2 million of those doses due in December have been delivered
Japan, however, was still the last country among the Group of Seven nations to give it the OK as it required an additional clinical trial to be conducted on Japanese people to ensure safety
Health Minister Norihisa Tamura says a formal approval is expected Sunday